RecruitMe

ICON3: A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

ICON3: A Phase 3 Study of Eltrombopag vs. Standard Therapy for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

Sponsor:	Baylor College of Medicine
Enrolling:	Male and Female Patients
Study Length:	1 Years
Clinic Visits:	14
IRB Number:	AAAS3726
U.S. Govt. ID:	NCT03939637
Contact:	Cindy Neunert, MD: 212-305-9770 / cn2401@cumc.columbia.edu

Additional Study Information: The purpose of this study is to investigate the safety and effectiveness of eltrombopag (investigational drug) in treating children and adolescents with newly-diagnosed immune thrombocytopenia (ITP), which is a rare blood disorder.

This study is closed

Investigator

Cindy Neunert, MD

See all studies by this doctor

Do You Qualify?

Is your child between the ages of 1 and 18?	Yes	No
Has your child been recently diagnosed with ITP?	Yes	No

Submit

Cancel

You may be eligible for this study

Place Holder

I would like to receive email alerts about studies like this. (Optional)

Required: I agree to the terms of use

CAPTCHA

What code is in the image?

Enter the characters shown in the image.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel

For more information, please contact:

Cindy Neunert, MD
cn2401@cumc.columbia.edu
212-305-9770

This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.

I AGREE